During the past decade, Specialized Hospital for Active Treatment of Hematological Diseases conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 7 clinical trials were completed, i.e. on average, 43.8% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 5 clinical trials were completed. i.e. 71.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Specialized Hospital for Active Treatment of Hematological Diseases" #1 sponsor was "AOP Orphan Pharmaceuticals AG" with 4 trials, followed by "Amgen" with 4 trials sponsored, "Celgene" with 2 trials sponsored, "Octapharma" with 2 trials sponsored and "CTI BioPharma" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Specialized Hospital for Active Treatment of Hematological Diseases" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Laboratoire français de Fractionnement et de Biotechnologies" with 1 trials as a collaborator, "PSI CRO" with 1 trials as a collaborator, "PharmaEssentia (Co-Sponsor for USA)" with 1 trials as a collaborator and "PharmaEssentia Corporation (Co-Sponsor for USA)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Specialized Hospital for Active Treatment of Hematological Diseases" are "Polycythemia Vera" (3 trials), "Relapsed Multiple Myeloma" (2 trials), "Von Willebrand Diseases" (2 trials), "Acute-graft-versus-host Disease" (1 trials) and "Beta-Thalassemia" (1 trials). Many other conditions were trialed in "Specialized Hospital for Active Treatment of Hematological Diseases" in a lesser frequency.

Most popular intervention types in "Specialized Hospital for Active Treatment of Hematological Diseases" are "Drug" (16 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carfilzomib" (3 trials), "Dexamethasone" (3 trials), "Lenalidomide" (3 trials), "Luspatercept" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Specialized Hospital for Active Treatment of Hematological Diseases" are 17 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Specialized Hospital for Active Treatment of Hematological Diseases". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Specialized Hospital for Active Treatment of Hematological Diseases, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Specialized Hospital for Active Treatment of Hematological Diseases, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".